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KEY TO MASTER CHART 
HEADINGS : 
O/H : Obstetric History 
GA : Gestational Age 
U/A : Urine Albumin 
BS : Bile Salts 
BP : Bile Pigments 
BT : Bleeding Time 
CT : Clotting Time] 
PT : Prothrombin Time 
Hb : Haemoglobin 
P.Smear: Peripheral Smear 
PPH : Postpartum Haemorrhage 
 SIGNS 
1. Jaundice 
2. Hepatomegaly 
3. Spleenomegaly 
4. Ascities 
5. Altered sensorium 
PREGNANCY OUTCOME 
PT : Preterm 
LN : Labour Natural 
ND : Neonatal death 
IUD : Intrauterine death 
DIC : Disseminated Intravascular   
           coagulation. 
SYMPTOMS 
1. Nausea, Vomitting 
2. Anorexia 
3. Fever 
4. Abdominal Pain 
5. High coloured urine 
6. Pruritis 
7. Loose stools 
8. Clay Stools 
9. Itching  
 B.term : Borderline term 
COMPLICATION 
1. Anaemia 
2. PIH 
3. Oliguria 
4. Chronic Active Hepatitis  with 
PHT – Devascularisation done 
5. Cirrhosis with PHT 
6. Gillbert’s disease 
 
INTRODUCTION 
Pregnancy occurring in patients with Jaundice is an important 
medical and obstetric problem producing adverse effects to both mother 
and fetus. It often leads to a high maternal mortality and fetal loss. The 
problem is world wide but in the prevailing conditions of poor nutritional 
status, anaemia, low hygienic conditions and inadequate treatment facilities 
in developing countries it assumes a major importance. 
Jaundice in pregnancy is an important medical disorder seen more 
often in the developing countries than in the developed. It is responsible for 
about 10 percent of Maternal death’s in India (Jeyaram K, 1988, Rao.K.B. 
1955). Because of its frequency, viral hepatitis commands priority 
recognition as the most important cause of Jaundice in pregnancy. 
Although there are many reports in the medical literature stating that 
pregnancy does not exert any adverse effect on the course of infective 
hepatitis, this is always one of the commonest cause of perinatal mortality, 
morbidity, maternal mortality, morbidity. 
Recent advance in the laboratory techniques to study the serological 
viral markers, Identification of leptospirosis, modern radiological technique 
to study the liver including CT scans, MRI, Ultrasound have facilitated the 
establishment of the etiology of Jaundice. 
In developing countries like India, infective etiology still plays a 
major role in causing Jaundice. Control of infections causing Jaundice will 
have an impact on the maternal and fetal health. Risk of perinatal 
transmission of Hepatitis B Virus to the Neonate can be greatly minimized 
by the use of immunoglobulin and vaccine for immunoprophylaxis. 
Jaundice complicating pregnancy has been the cause for maternal 
mortality in 11.76% cases during a 3 year study in Govt. R.S.R.M. Lying 
in Hospital, Royapuram, Chennai. Therefore this study in undertaken with 
an aim to analyse the etiology, course of the disease and maternal and 
perinatal outcome of jaundiced pregnant women. It is sincerely hoped that 
this study will help in improving the maternal and perinatal outcome in 
jaundice complicating pregnancy. 
REVIEW OF LITERATURE 
Incidence 
 Absolute figures for the incidence of jaundice in pregnancy are 
difficult to obtain and different in various countries. Sheila Sherlock in her 
classical work on liver and its disorders, states that the incidence of 
Jaundice in pregnancy is 1 out of every 1500 pregnancies (0.067%). 
Incidence in India varies between 0.92% to 1.46%. With the advent of 
Australian Antigen (Hepatitis B Surface Antigen) by Blumberg in 1965, 
the etiological classification was made easier. The incidence of Hepatitis B 
infection in pregnancy in India is reported to be 1 in 425 pregnancies 
(0.245%). 
The true incidence in pregnant women in India may be higher because 
1) Many anicteral and mildly icteric patients would not attend the 
hospital. 
2) Missed diagnosis is particularly liable to occur in early 
pregnancy where Nausea, Vomiting and anorexia are usually 
attributed to hyperemesis gravidarum. 
Liver function tests and Pregnancy 
 Non-Pregnant Change in Pregnancy 
Bilirubin 2-17µmol/L No change 
Enzymes   
Transaminase  7-40 IU/L No change 
Gamma GT <30 IU//L “ 
5-Nucleotidase 2-17IU/L “ 
S. Alkaline Phosphatase 30-130IU/L Rise, Progressive increase 
after 5th week to term (1.5 
x Normal 
- Placental 
Component 
- Skeletal Component
Prothrombin time 8-14sec No change 
Proteins   
Total Proteins 65-80g/L Fall (by 10g/l by 16-20th 
wk) 
Albumin 35-55g/L Fall by 10g/L mostly in 
first trimester 
Globulin 30-50g/L Rise (Progressive Increase 
to term) 
Fibrinogen 2-4g/L Rise (Progressive Increase 
to term) 
Lipids   
Cholesterol 4-6.5mmol/L Rise (Progressive Increase 
to term) 
Triglyceride <1.5mmol/L Rise 
Physiological, Biochemical and anatomical changes in liver during 
pregnancy 
In normal pregnancy, with adequate nutrition, the metabolic changes 
seem to be without any effect on liver metabolism and function. In the non 
pregnant individual hepatic blood flow represents 25-35%of cardiac output. 
In pregnancy, the increased blood volume is partly redistributed into the 
splanchnic circulation and great veins. So the portal venous pressure of the 
gravid uterus on the vena cava results in diversion of a portion of venous 
return through the azygos system. Venous pressure increases in the 
esophagus leading to transient engorgement of esophageal veins (varices) 
in approximately 60% of healthy pregnant women. 
Serum levels of alkaline phosphatase, transaminase and LDH rise 
during labour and delivery. The alkaline phosphatase may remain elevated 
upto 6 weeks postpartum. The alkaline phosphatase is elevated because of 
the contribution from placenta. Due to delayed excretion of billirubin, upto 
15% of normal pregnant women may have billirubin level of over 1.0mg% 
and this may account for the increased incidence of pruritis during 
pregnancy. 
In the III trimester, the liver occupies a more posterior superior 
position. A palpable liver is abnormal in pregnancy and usually indicates 
underlying liver disease. Palmar erythema and spider naevi are common in 
normal pregnancy. 
Concepts of Jaundice 
Jaundice is the yellow discolouration of the skin, sclera and mucous 
membranes due to increased level of serum Billirubin (more than 
2.5mg/dl). Internal tissues and body fluids are coloured yellow, except the 
brain, as billirubin does not cross the blood brain barrier, except in the 
immediate neonatal period. 
Classification of Jaundice 
Based on the etiology, Jaundice in pregnancy can be classified as. 
I. Jaundice peculiar to pregnancy. 
a) Toxemia of Pregnancy 
b) Intrahepatic cholestasis of pregnancy. 
c) Acute fatty liver of pregnancy 
II. Intercurrent Jaundice in pregnancy 
a) Viral Hepatitis 
b) Other infections 
 
III. Pregnancy on pre existing liver disease. 
a) Cirrhosis and portal hypertension 
b) Familial non hemolytic Jaundice  
IV. Miscellaneous 
Jaundice due to Hemolysis, hepatotoxic drugs, Gall bladder disease. 
Ia – Severe preeclampsia – Eclampsia 
Liver involvement in preeclampsia – Eclampsia is frequently 
accompanied by other organ involvement; commonly reffered to as HELLP 
– Syndrome (Hemolysis, elevated liver enzymes and low platelets) 
Incidence: 
It constitutes 0.1 – 0.6% of all pregnancies and 4 – 12% of patients 
with pre eclampsia. 69% of women present in the antepartum period (89% 
after 27 weeks and 11% before 27 weeks) and 31% in postpartum within 
48 hours. 
Signs and Symptoms: 
Typically right upper Quadrant pain occurs in 65 to 90%, nausea and 
vomiting in 36 – 50%, Head ache in 31%, Jaundice in 5%. Other signs 
include weight gain with edema. Hypertension may be absent in 20%. 
Criteria for diagnosis: 
A) Haemolysis –  
1. Abnormal peripheral smear. 
2. Increased serum Billirubin > 1.2mg/dl. 
B) Elevated liver enzymes. 
Increased SGOT > 60IU/L 
Increased LDH > 600IU/L 
C) Low platelets (DeBoer et al., 1991) 
Class I <50,000 cells/cu.mm 
Class II 50,000 to 1,00,000/cu.mm 
Class III 1,00,000 to 1,50,000/cu.mm 
 
Classification of HELLP (Weinstein et al., 1982) 
Partial : One (or) Two features 
Complete : All three features 
Maternal and Fetal Outcome: 
The most important cause of maternal morbidity and mortality is the 
Development of DIC. Eclampsia, Pulmonary edema, acute renal failure and 
abruptio placenta can occur. Maternal mortality ranges from 0% to 24%. 
More than 1/3 of fetuses are born premature or exhibit IUGR. Prematurity 
increases the risk of perinatal mortality which ranges from 30-60% in 
different series. Prompt delivery is the effective treatment. Risk of 
recurrence is 3.4%. 
b. INTRA HEPATIC CHOLESTASIS OF PREGNANCY (ICP) 
 ICP is a benign cholestatic disorder that occurs in second and third 
trimester of pregnancy and disappears shortly after delivery. The incidence 
of ICP varies geographically with rates as low as 1-2 per 10,000 
pregnancies in India, North America and Australia and as high as 2% of 
Births in Sweden and 14% in chile. 
Etiology: 
Genetic predisposition: High incidence has been reported in 
specific ethnic groups in chile & Sweden. The risk of ICP was increased in 
women whose mothers or sisters had experienced this disorder. Another 
theory is a combined defect in sulfation of estrogens and progestogens 
together with a defect in canalicular excretion of these metabolites. Patients 
with ICP may have abnormal progesterone metabolism. So progesterone 
should not be given in pregnant women with history of ICP (Reyes H et al 
2000) 
Clinical features: 
Pruritis occurs in 100% and Jaundice in 10-15% of Patients. The 
problem typically occurs in III trimester, though 25% of cases presented in 
II trimester. Serum Billirubin is usually <5mg/dl. Transaminase is 5 times 
normal, in 40% it is more than 10 time normal. Serum Alkaline phoshatase 
rises to 2 times the normal. Serum Bile acids are elevated. Measurement of 
fasting serum total bile acid concentration is a valuable diagnostic test, 
particularly when a pregnant women experience pruritis with normal 
aminotransferase levels. 
Fetal outcome : 
ICP has been associated with poor fetal outcomes including 
increased incidence of meconium stained amniotic fluid (25%), preterm 
labour(20%), fetal distress (22-33%) and still birth (1-2%) (Rioseco AJ, 
1994). 
Maternal Outcome : 
The risk of postpartum hemorrhage is 10-22% as a result of Vitamin 
K malabsorption.  Maternal prognosis is good. Symptoms resolve within 2 
days of delivery, enzyme levels normalize within 4-6 weeks; Recurrence 
rate in subsequent pregnancy is 60-70%. 
MANAGEMENT 
Medical : 
1) Ursodeoxycholic acid (UDCA) is the  drug of choice.  14mg/kg/d of 
UDCA improved maternal pruritis and fetal outcome.  UDCA also 
improves maternal bile acid concentration profile, improves 
progesterone metabolism and markedly decreases the serum levels 
of sulfated steroids.  UDCA is not teratogenic (Serrano MA, et al 
1998). 
2) Other drugs in use are Antihistamines, benzodiazepines, low dose 
Phenobarbital, dexamethasone and S-adenosyl methionine (SAM). 
Obstetric : 
Fetal outcome is improved by early diagnosis, and aggressive 
management including intense fetal surveillance, delivery after lung 
maturity and administration of drugs that decrease bile salts. Rioseco et al 
proposed that patients without Jaundice should be delivered at 38 weeks of 
gestation whereas jaundiced patients should be delivered at 36 weeks 
provided that pulmonary maturity has been achieved. 
C. ACUTE FATTY LIVER OF PREGNANCY (AFLP) 
Incidence is 1 in 7000 to 14,000 deliveries. It is a rare and 
potentially  fatal disease, complicating a normal pregnancy in the third 
trimester. 
Etiology : 
Not known precisely. A genetic component has been suggested 
although no familial cases have been reported.  Recent research suggest that 
AFLP is associated with mutation in long chain 3-hydroxy acyl COA 
dehydrogenase (LCHAD), a fatty acid oxidation enzyme.  Liver disease in 
pregnancy occurs most often when the fetal deficiency of enzymatic 
activity is severe. 
Clinical Features: 
AFLP occurs usually between 30 and 38 weeks of gestation. The 
frequency is higher in primipara and in women carrying a male fetus.  It 
presents with sudden onset of nausea and vomiting in 70%, epigastric pain 
or right upper quadrant pain in 50-80%.  Jaundice usually occur 1-2 weeks 
after the onset of these non-specific symptoms but pruritis is rare.  50% of 
patients develop preeclampsia. Serum Billirubin is usually between 5-
15mg/dl, serum aminotranferases < 1000 IU/L, prolonged clothing time and 
leukocytosis.  Hypoglycemia and renal dysfunction can occur. 
Maternal and Fetal Outcome : 
Maternal mortality is very high (50-70%) but recently the rates have 
come down mainly due to earlier diagnosis and improved intensive care 
support (Pereira SP, Williams R, 1997).  Delivery arrests rapid detoriation 
of liver function.  If not terminated promptly, pregnancy may culminate in 
fulminant hepatic failure with its attendant complications and a high 
maternal and fetal mortality.  Most patents improve one to four weeks 
postpartum and recovery is complete. 
Treatment : 
There is no specific therapy. Early recognition and prompt delivery 
are recommended to improve maternal and fetal survival.  Severely affected 
patients should be attended in intensive care units with aggressive treatment 
of complications. 
II (a) VIRAL HEPATITIS : 
This is the commonest cause of jaundice in pregnancy. There are 5 
distinct types of viral hepatitis – A, B, C, D, E.  All but Heptatitis B are 
RNA viruses. During acute phases, these forms of hepatitis are often 
clinically similar. 
In many cases, infections are subclinical but if clinically apparent 
symptoms may precede jaundice by 1 to 2 weeks. Symptoms include 
nausea, vomiting, headache and malaise.  Low grade fever is more common 
with Hepatitis A. When jaundice appears symptoms improve, but the pain 
and tenderness over liver may persist.  Serum aminotransferase levels vary 
and their peaks do not correspond with disease severity. Peak levels of 400 
to 4000 IU/L are usually reached by the time jaundice develops. Serum 
Billirubin levels usually peak at 5 to 20mg/dl and they typically continue to 
rise despite falling aminotransferase levels. 
Adverse maternal outcome relates to the propensity for developing 
severe viral hepatitis during pregnancy. Reports on severity differ between 
developing and developed countries.  Most data from India and North 
Africa reports that epidemics of Hepatitis E are severe among pregnant 
women. Acute viral hepatitis in an adult in a high prevalence country such 
as India is more likely to be due to HEV or HBV rather than HAV. There is 
widespread exposure to HAV in childhood in our country and hence long 
term immunity. Maternal mortality in pregnant women with viral hepatitis 
is 14.3% whereas in non pregnant women it is 5.6%. 
Adverse fetal outcome are mainly due to risk of vertical transmission 
from mother and increased risk of preterm delivery. No excess evidence of 
congenital abnormalities has been reported. 
No specific therapies are recommended for Hepatitis A through E 
during pregnancy.  Interferons, ribavarin, nucleoside analogues, ganciclovir 
and foscarnet are contraindicated in pregnancy.  Only lamivudine is 
recommended in mothers with chronic active hepatitis B to prevent 
transmission to the fetus and has been shown safe and effective. There is no 
indication for termination of pregnancy in viral hepatitis.  
HEPATITIS A 
 It is caused by RNA virus and is transmitted by faeco-oral route.  It 
occurs as epidemics mostly in children rather than adults. Almost universal 
exposure occurs in infancy and childhood in developing countries like 
India. 
The incubation period is 2-7 weeks.  Signs and symptoms are not 
specific and it may go undiagnosed.  Majority are anicteric. Early detection 
is by identification of IgM antibody which indicates acute infection. During 
convalescence IgG antibody predominates.  It persists and is responsible for 
lifelong immunity. 
Effect of Pregnancy : 
Hepatitis A is a self limiting illness noted for its complete recovery.  
It has the same course during pregnancy as in nonpregnant patient.  A 
chronic carrier state is not recognized. Acute liver failure is rare and 
especially not common in pregnancy. Risk of vertical transmission is 
negligent. The risk of preterm birth is increased in acute infection (Hieber 
JP et al, 1987). Pregnant women exposed to infection should be given 
prophylaxis with 1ml of immunoglobulin immediately following exposure 
(CDC, MMWR 1999).  It gives a protective efficacy rate of around 80% 
short term. Neonatal immunoprophylaxis is rarely needed except in preterm 
as most neonatal infections are mild and life long immunity follows 
recovery. 
HEPATITIS – B : 
The agent is a DNA hepadna virus. The incubation period is 3-6 
months.  The route of transmission by infected blood or blood products. 
Other infective secretions are saliva, vaginal secretions and semen.  It is 
therefore a sexually transmitted disease. 
The first virological marker to appear is HBsAg.  HBsAg levels 
decline after the onset of illness and usually undetectable three months after 
exposure; if it persists beyond three months it indicates chronic disease. 
Although HBeAg is invariably present during early acute hepatitis, its 
persistence indicates chronic infection and active viral replication. 
Approximately 90% of persons with hepatitis B infection recover 
completely.  Of the 10% who develop chronicity, one fourth develop 
chronic liver disease which is the most serious consequence of Hepatitis B 
infection. 
Effects on Pregnancy : 
Neither the prevalence nor the clinical course is altered by 
pregnancy.  Hepatitis B was seen in 17-20% of pregnant women with viral 
hepatitis.  Over 90% of the women recovered fully.  But in those associated 
with anaemia, malnutrition and diabetis the course may be prolonged and 
severe. Preterm delivery is increased. Transplacental transmission is 
common in acute hepatitis and also in chronic seropositivity. Transmission 
is maximum through blood and vaginal secretions.  In first trimester, 
transmission rate is only 10% whereas in 3rd trimester, it is 80-90% 
(ACOG, educational Bulletin, 1998).  Thus antepartum HBsAg testing is 
mandatory. HBV vaccine is safe and effective in seronegative mothers. 
Vertical transmission correlates well with HBeAg positivity 
indicating high viral load in mother.  Those HBeAg negative and anti HBe 
antibody positive do not appear to transmit the infection.  95% of perinatal 
transmission occurs intrapartum. Following delivery most infected infants 
are asymptomatic. Others develop fulminant hepatitis and nearly 85% 
become chronic carrier. 
Prevention of neonatal infection : 
Infants born to infected mothers should receive HBV  human 
hyperimmune globulin (HBIG) at delivery along with first dose of HBV 
vaccine. 
 Dose Time 
HBIG 0.5ml Within 12 hr 
Vaccine 5-10mcg IM Within 12 hr  
(0, 1 and 6 months) 
 
CDC and ACOG recommends hepatitis B serological screening for 
all prenatal patients.  For high risk mothers, who are seronegative, vaccine 
can be provided during pregnancy – 20mcg IM at 0, 1 and 6 months.  
Recently lamivudine, a nucleoside analog has been used with good 
safety and efficacy in the last 4 weeks of pregnancy to decrease the risk of 
vertical transmission (Van Nunen AB, 2000). 
HEPATITIS D : 
It is a defective RNA virus that is very small and relies on HBV for 
helper functions. The virus always co-infects with hepatitis B.   Chronic 
infection with B and D hepatitis produces more severe disease and 
approximately 75% of those affected develop cirrhosis.  Prevention of HBV 
via immunoprophylaxis protects against HDV infection. 
HEPATITIS C :  
It is a RNA virus of flavivirus family.  Transmission is similar to 
hepatitis B.  It is more prevalent in IV drug abusers, multiply – transfused 
individuals, HIV seropositive subjects and those with high risk sexual 
behaviour. The incidence of persistent disease is common after hepatitis C 
infection. 
Effect on Pregnancy : 
Prevalence of HCV infection in pregnant women is 1-2%.  HCV 
infection does not interfere with normal pregnancy.  Perinatal outcome is 
not adversely affected.  Vertical transmission occurs only when there is 
HIV co-infections and high maternal HCV RNA levels. Vertical 
transmission rate is 3-6%. 
Unlike for HBV, conventional tests for detecting HCV antigens are 
not available.  Instead diagnosis relies on detecting antibodies to HCV 
(Anti HCV) and HCV RNA using PCR – based molecular techniques. 
HEPATITIS E 
It is one of the common cause of viral hepatitis in adults. HEV is a 
water borne RNA virus that is enterically transmitted.  The incubation 
period is 2-9 weeks.  HEV hepatitis is generally mild and self limited but 
commonly causes fulminant hepatic failure during pregnancy.   
Effect on Pregnancy : 
The infection rate for men is 2.8% non pregnant women 2.1% and in 
pregnant women 17.3%. The frequency of disease is 8.8% in I trimester, 
19.4% in II trimester and 18.6% in III trimester (Khuroo MS, 1995).  The 
risk of abortion, preterm birth, IUGR and perinatal mortality are increased 
(Mayapadhy et al, 1996).  Preliminary evidence suggests a high incidence 
of vertical transmission, around 50% (Singh S, Mohanty A, 2003).  The 
incidence of fulminant hepatic failure in pregnancy is 22% and in non-
pregnant it is 2.8%.  Hepatic failure was exclusively noticed in last 
trimester. 
b) OTHER INFECTIONS  
Malaria : 
Malarial infection can be endemic or sporadic.  The causative 
organism is plasmodium species.  The incubation period varies from 8-25 
days. The infection is transmitted by anopheles mosquito. Clinical features 
are fever and flu like symptoms including malaise, headache and vomiting, 
which may occur in intervals. Symptoms are less severe in immune 
patients. Malaria may be associated with anaemia and Jaundice.  Jaundice is 
due to hepatitis and haemolysis.  Liver and spleen enlarge and become 
tender. 
Effect on pregnancy :   
Pregnant women have an increased incidence of infection and 
parasitaemia may be great.  Severe anaemia in pregnancy is a major 
obstetric problem in malaria endemic area. Haemolytic anaemia which can 
cause jaundice may be severe in pregnancy and hepatorenal syndrome is 
often the cause of death.  Malaria may present as puerperal pyrexia 
following delivery in women with low immunity. Post partum haemorrhage 
is an important complication in women with malaria.  Malaria can infect 
placenta leading to maternal anaemia, spontaneous abortion, stillbirth, 
intrauterine death and low birth weight.  Intrauterine death is mainly caused 
by massive infection of the placenta and persistent high fever.  Malarial 
parasites can cross placenta particularly in non-immune mothers leading to 
congenital malaria. 
WHO recommends malarial chemoprophylaxis throughout 
pregnancy in endemic areas.  It is given as weekly prophylaxis with 
chloroquine in a dose of 300mg/wk. 
LEPTOSPIROSIS : 
5-10% of patients with leptospirosis will have hepatic and renal 
involvement.  It is transmitted by direct contact with urine, blood or tissue 
of an infected animal. They enter through abrasions in skin or through 
intact mucous membrane.  Incubation period is 2-20 days. More than 90% 
of patients have relatively mild and anicteric form of leptospirosis.  Severe 
leptospirosis may present as jaundice, renal dysfunction and haemorrhagic 
diathesis referred as Weil’s syndrome. 
There is marked elevation of serum billirubin and alkaline 
phosphatase with moderate elevation of aminotransferases in patients with 
liver involvement. Diagnosis is based on either isolation of the organism or 
a rise in antibody titre in Microscopic slide agglutination test (MAT). The 
latter  is commonly used.  
Effect on pregnancy : 
Perinatal mortality is high in leptospirosis.  30% of pregnancies 
ended in abortion or preterm death (Shaked Y, Samra D, 1993). Vertical 
transmission is rare. 
Penicillin G in a dose of 1.5million units IV quid is still the drug of 
choice.  Other alternative are ampicillin and erythromycin. Doxycycline is 
contraindicated in pregnancy. 
Typhoid : 
Enteric fever is endemic in most developing  regions especially in 
India.  It is transmitted by ingestion of contaminated water or food.  
Incubation period is 3-21 days. The most prominent symptom is prolonged 
fever. It is seen in 75% of cases. Gastrointestinal symptoms are quite 
variable.  Only 20-40% of patients have abdominal pain.  Hepatic 
dysfunction, through less common can occur in patients with typhoid fever.  
Liver function tests will be moderately elevated. 
Effects on Pregnancy : 
The acute infection in pregnant women run a similar course to those 
in non pregnant women.  Transplacental infection has been recorded.   
Around 3% of patients with severe form of typhoid fever may go for 
spontaneous abortions and preterm labor. But effective antibiotic treatment 
has made this outcome less common.  
Chloramphenicol still remains the most effective treatment, but 
many clinicians prefer ciprofloxacin, ceftriaxone or azithromicin. 
Herpes Viruses : 
All  members of herpes group – Herpes simplex, varicella, 
cytomegalovirus and epstien barr virus can cause hepatitis.  More than half 
are associated with immunosuppression. Jaundice is not invariable and 
mucocutaneous stigmata may be absent. Herpes simplex hepatitis carries a  
grave prognosis.  Mortality exceeds 90% even with treatment.  Herpes 
simplex type II is most common in 3rd  trimester. Symptoms are three times 
more common in pregnancy. The virus can cross placenta but it has no 
relation with congenital malformation. HSV II  acquired at birth from 
cervical and vaginal contamination can lead to disseminated infection in 
babies with 90% mortality.  Pregnancy is a high risk factor and has been 
associated with a high maternal and fetal mortality rate. Acyclovir appears 
to improve the outcome. 
III) CIRRHOSIS AND PORTAL HYPERTENSION 
Pregnancy in a cirrhotic patient is rare because of reduced fertility 
and older age.  In patients with non-cirrhotic portal hypertension (NCPHT), 
liver function and fertility are relatively well preserved. 
In pregnant women, post necrotic cirrhosis due to chronic B or C 
viral hepatitis  is the most common cuase (Williams Obstetrics, 2005).  
Causes for non-cirrhotic portal hypertension are : 
1) Extra hepatic portal vein obstruction  
2) Non-cirrhotic portal fibrosis 
3) Congenital hepatic fibrosis 
4) Polycystic liver disease, etc. 
Perinatal Outcome : 
Fetal loss is high in advanced cirrhosis.  Spontaneous abortions, 
stillbirths, IUGR and neonatal deaths are all increased (Schreyer. P, 1982). 
The perinatal mortality rate in cirrhotic patients is 10-38% (Russel, MA, 
Craige SD, 1998). But Indian studies reported that patients with NCPHT 
had nearly same pregnancy outcome as general population except for 
increased incidence of abortion (20%). Fetal outcome was improved in 
patients who underwent endoscopic obliteration of varices or 
decompression shunt surgery prior to conception. 
Maternal Outcome : 
Pregnancy profoundly affects systemic haemodynamics and may 
contribute to rapid detoriation of portal hypertension including increased 
risk of variceal haemorrhage. These haemodynamic changes are maximum 
in 2nd trimester and hence the risk of haemorrhage is greatest during this 
period. 
Maternal Complications include : 
1) Hepatic failure and hepatic encephalopathy 
2) Variceal haemorrhage 
3) Post partum haemorrhage 
4) Rupture of splenic artery aneurysm 
5) Spontaneous bacterial periotonitis. 
Women with cirrhotic portal hypertension develop maternal 
complication more frequently than women with NCPHT. Post partum 
haemorrhage occurs in 7-26% of patients and is more common in cirrhotic 
patients. Jaundice and hepatic encephalopathy are often precipitated by 
haemorrhage and hypotension. 
Maternal mortality is 4-7% in NCPHT whereas it is 10-18% in 
patients with cirrhosis. (Sriram PV, Goenka, MK, Singh K, 1999). Portal 
Decompression before pregnancy decreases mortality. 
Congenital non-haemolytic Hyperbilirubinemia : GILBERT’S 
DISEASE:  
Gilberts disease presents as mild fluctuating Jaundice which may 
only be noticed when the patient is tired, dehydrated or calorie depleted. As 
all of these may occur during normal pregnancy, gilbert’s disease may be 
diagnosed for the first time during pregnancy.  Serum  billirubin is elevated, 
but liver enzymes are normal, there is no sign of any systemic disease and 
no symptoms other than jaundice. Maternal and perinatal outcome are not 
affected by the disease.  It is relatively common in Western Societies with 
the prevalence rate of 1-2%. There are no significant risks with the 
diagnosis but precipitating factors should be minimized or avoided. 
AIM OF THE STUDY 
1) To study the incidence of jaundice in pregnancy in relation to Age, 
parity and duration of pregnancy. 
2) To study the effect of jaundice in pregnancy in terms of perinatal 
morbidity and mortality. 
3) To study the maternal mortality and morbidity in pregnancies 
complicated by Jaundice. 
 
 
 
 
 
 
STUDY DESIGN 
Prospective Cohort Study 
 
 
MATERIALS AND METHODS 
MATERIALS 
All cases of pregnancy with jaundice in all the trimesters of 
pregnancy admitted to the Govt. RSRM lying-in Hospital, Chennai during 
the period of 2004 to 2006 were taken up for study. 
METHODS  
The cases were studied as per the proforma appended. Demographic 
features such as Age, Parity, socioeconomic status, previous obstetric 
history, gestational age were documented at admission. 
Past history including history of jaundice in the previous pregnancy, 
history of contact with jaundice, history of injections, history of blood 
transfusions, history of intravenous drug abuse and family history of 
jaundice were noted. 
In the present history, symptoms like fever, nausea, vomiting, 
anorexia, diarrhea,  colour of urine and motion, pruritis and history of 
bleeding episodes were asked for. The above data were collected in a 
structured proforma. 
Thorough general and systemic examination was carried out for each 
patient.  In addition evidence for anaemia, hepatomegaly, spleenomegaly 
ascites and purpuric spots were recorded. 
Medical gastroenterologist opinion was sought and management 
protocol was noted.  Investigations included urine for albumin, sugar, bile 
salts and bile pigments,  complete  haemogram with platelet count, bleeding 
time, clotting time, prothrombin time, pheripheral smear for malarial 
parasites, VDRL, blood widal, liver function tests including serum 
billirubin, transaminases, alkaline phosphatase, serum proteins, albumin, 
serum fibrinogen, blood urea and serum creatinine. 
All patients were screened for viral markers for hepatitis B and C 
infections and also for leptospirosis.  Likewise the diagnosis of intrahepatic 
cholestasis of pregnancy and acute fatty liver of pregnancy were done by 
clinical presentation and biochemical parameters.  Liver function test was 
repeated every week in all patients till the time of recovery and discharge 
from the hospital. The patients were followed up for pregnancy outcome.  
Ultrasound abdomen was done in patients with chronic liver disease. 
OBSERVATIONS 
A  prospective study of all  antenatal patients admitted with jaundice 
in pregnancy at the Government R.S.R.M. Lying-in Hospital, Chennai from 
January 2004 to August 2006 was undertaken. 
Total number of antenatal admissions during this period is 40219. 
Total number of patients who had Jaundice is 51 and these form the present 
study group.  
1)  INCIDENCE OF JAUNDICE COMPLICATING PREGNANCY 
The incidence of jaundice complicating pregnancy during this period 
in our hospital is 1.26 per 1000 population.  It is given yearwise in Table 1. 
TABLE – 1 
Year Total 
antenatal 
admissions 
No. of 
Jaundiced 
Pregnant 
Women 
Percentage Incidence 
per 1000 
population 
per year. 
2004 14264 19 0.13 1.3 
2005 14928 18 0.12 1.2 
2006 11027 14 0.12 1.2 
 
2) DISTRIBUTION OF CASES ACCORDING TO ETIOLOGY 
Among the total antenatal admissions of 40219, 51 patients 
developed jaundice. This constitutes the incidence of jaundice complicating 
pregnancy as 1.26 per 1000 population  during this study.  Out of 51 
patients, 36 cases were due to viral hepatitis.  11 cases were HBsAg 
positive and 2 were positive for Anti HCV. 
TABLE – 2 
Sl.No. Diagnosis No. of 
Cases 
Percentage Incidence 
per 1000 
population 
1.  Viral Hepatitis 35 68.5 0.9 
2.  HELLP Syndrome 4 7.8 0.1 
3.  Chronic liver disease 
and PHT 
3 5.8 0.074 
4.  Intra hepatic 
cholestasis of 
pregnancy 
2 3.9 0.049 
5.  Malaria 2 3.9 0.049 
6.  Leptospirosis 2 3.9 0.049 
7.  Typhoid 1 1.9 0.024 
8.  Combined malaria 1 1.9 0.024 
and leptospirosis 
9.  Gilbert’s Disease 1 1.9 0.024 
3) AGE INCIDENCE 
The patients in study group were in the age ranging from 19 – 35 
years.  Nearly 58% of jaundiced patients were between 20-24 years.  30% 
of patients were between 25-29 years. 
TABLE – 3 
Sl.No. Age Group in 
Years 
No. of cases Percentage 
1. 15-19 2 3.9 
2. 20-24 30 58.8 
3. 25-29 15 29.4 
4. 30-35 4 7.8 
 Total 51 100 
 
4) INCIDENCE IN RELATION TO GRAVIDITY 
Maximum number of cases occurred in primigravida (58.8%). This 
is shown in Table 4. 
TABLE – 4 
Sl. No. Gravidity No. of cases Percentage 
1. Primigravida 30 58.8 
2. Second Gravida 12 23.5 
3. Third Gravida 8 15.6 
4. Fourth Gravida 1 1.9 
 Total 51 100 
5) INCIDENCE IN RELATION TO GESTATIONAL AGE 
Majority of patients (76.4%) were in 3rd trimester.  20% were in 2nd 
trimester.  2 patients developed jaundice post partum. 
TABLE – 5 
Sl.No. Period of Gestation No. of Cases Percentage 
1. I Trimester - - 
2. II Trimester 10 19.6 
3. III Trimester 39 76.4 
4. Post partum 2 3.9 
 Total 51 100 
6) ANALYSIS OF PRESENTING SYMPTOMS 
The number of cases with percentage of various symptoms are 
shown in Table 6. 
TABLE – 6 
Sl. No. Symptoms No. of Cases Percentage 
1)  History of fever 35 71 
2)  Nausea and vomiting 28 54.9 
3)  Anorexia 28 54.9 
4)  Pruritis 22 43.1 
5)  High coloured urine 21 41.1 
6)  Upper abdominal pain 16 31.3 
7)  Clay stools 2 3.9 
8)  Loose stools 2 3.9 
 
7) ANALYSIS OF CLINICAL SIGNS : 
The clinical signs were not similar in all patients. Jaundice was 
present in almost all cases followed by hepatomegaly. The number of cases 
with percentage of various clinical signs are shown in Table 7. 
TABLE – 7 
Sl. No. Clinical Signs No. of Cases Percentage 
1.  Jaundice 49 96 
2.  Hepatomegaly 8 15.6 
3.  Spleenomegaly 4 7.8 
4.  Ascites 2 3.9 
 
8) ANALYSIS OF ASSOCIATED COMPLICATIONS 
Anaemia was the most common complication followed by pre 
eclampsia. 
TABLE – 8 
Sl.No. Complication No. of Cases Percentage 
1. Anaemia 14 27.4 
2. Pre-eclampsia 4 7.8 
3. Encephalopathy 2 3.9 
4. Hepatorenal failure 1 1.9 
5. Post Partum 
Haemorrhage 
10 19.6 
6. Coagulation failure 2 3.9 
 
9) SERUM BILLIRUBIN LEVEL 
 In more than 70% of patients, the level of serum billirubin is in the 
range of 2-6mg%.  None of the patients showed serum billirubin level 
above 20mg%. 
TABLE - 9 
Sl.No. Serum Billirubin 
(mg/dl) 
No. of cases Percentage 
1. 2-4 15 29.4 
2. 4-6 23 45 
3. 6-10 8 15.6 
4. 10-14 2 3.9 
5. > 14 3 5.8 
 Total 51 100 
10)  SERUM TRANSAMINASE LEVEL 
More than 50% of patients had serum transminase level between 
100-400 IU/L. 
TABLE – 10 
Sl.No. Serum 
Transaminase (IU/L)
No. of Cases Percentage 
1.  < 100 19 37.2 
2.  100-400 29 56.8 
3.  > 400 3 5.8 
 Total 51 100 
 
11) ANALYSIS OF FETAL OUTCOME OUT OF 51 CASES 
Fetal outcome was determined based on abortion, term live birth, 
term neonatal death, term IUD and preterm deliveries. 
Total number of fetal death is 13.  
Total number of babies discharged alive is 35 including preterm and 
term babies. 
Perinatal mortality is 25.4%. 
TABLE - 11 
Sl.No. Fetal Outcome No. of Cases Percentage 
1. Abortion 2 3.9 
Term Deliveries 28 54.9 
Term Alive 24 50.9 
Term IUD 1 1.9 2. 
Term  neonatal 
death 
1 1.9 
Preterm deliveries 21 41.1 
IUD 3 5.8 
3. 
Stillborn 1 1.9 
Neonatal death 7 13.7  
Discharged alive 11 21.5 
12)  ANALYSIS OF BIRTH WEIGHT AND FETAL OUTCOME 
Around 60% of babies were in birth weight between 2-3 kg.  Most of 
the fetal death (90%) were in birth weight group of 1-2 kg. The influence of 
birth weight on fetal outcome is shown in Table -12. 
TABLE – 12. 
Sl.No. Baby weight in 
Kg 
No. of 
Cases 
Percentage Alive Death 
1.  1-1.5 6 11.76 0 6 
2.  1.6-2 9 17.64 4 5 
3.  2.1-2.5 15 29.4 15 - 
4.  2.6-3 15 29.4 14 1 
5.  3.1-3.5 2 3.9 1 1 
6.  > 3.5 2 3.9 2 - 
 
13) MATERNAL OUTCOME OF 51 CASES (From January 2004 to 
August 2006). 
TABLE - 13 
1. Total number antenatal admissions 40219 
2. Total number of maternal mortality 25 
3. Incidence of maternal mortality 62/100,000 
4. Total number of jaundiced cases 51 
5. Total number of mortality due to jaundice 6 
6. Percentage of mortality in jaundice 11.76 
7. Percentage of mortality due to jaundice in 
relation to total maternal mortality 
23% 
 
14) RELATION OF MATERNAL AGE TO MATERNAL 
MORTALITY 
Maternal mortality was found to be higher in those women between 
20-24  years (50%).   Age group wise analysis of maternal mortality is 
given in Table 14. 
TABLE – 14 
S.No. Age group 
in years 
No. of 
cases 
Maternal 
Mortality
% of maternal 
mortality in age group. 
1. 15-19 2 1 16.6 
2. 20-24 30 3 50 
3. 25-29 15 2 33.3 
4. 30-35 4 - - 
 Total 51 6 100 
15)  MATERNAL MORTALITY IN RELATION TO GRAVIDITY 
Gravidity wise analysis revealed more number of mortality occurred 
in primigravida (66%). The results are shown in Table 15. 
TABLE - 15 
Sl. 
No. 
Gravidity No. of 
cases 
Maternal 
mortality 
Percentage 
1. Primigravida 30 4 66.6 
2. Second gravida 12 1 16.6 
3. Third gravida 8 1 16.6 
4. Fourth gravida 1 - - 
 Total 51 6 100 
 
16) RELATION OF SERUM BILLIRUBIN LEVEL TO MATERNAL 
MORTALITY 
50% of maternal mortality occurred with serum billirubin above 
10mg/dl.  However 16% of maternal mortality occurred with Billirubin 
levels of 2-4mg/dl. 
TABLE – 16 
Sl.No. Serum 
Billirubin mg/dl 
No. of 
cases 
Maternal 
Mortality 
Percentage 
of maternal 
mortality 
1. 2-4 15 1 16.6 
2. 4-6 23 1 16.6 
3. 6-10 8 1 16.6 
4. 10-14 2 1 16.6 
5. >14 3 2 33.3 
 Total 51 6 100 
17) RELATION OF SERUM TRANSAMINASE LEVELS TO 
MATERNAL MORTALITY 
Most of the maternal mortality was observed with value of above  
100 IU/L. 
TABLE – 17 
 
Sl.No. Serum 
Transaminase 
IU / L 
No. of cases Maternal 
Mortality 
Percentage 
1.  < 100 19 1 16.6 
2.  100-400 29 3 50 
3.  >400 3 2 33.3 
 Total 51 6 100 
 
18) RELATION OF TYPE OF DISEASE TO MATERNAL 
MORTALITY 
66.6% of maternal mortality were due to viral hepatitis.  Among 
these 50% died of Hepatitis B infection. 
TABLE – 18 
Sl. 
No. 
Diagnosis No. of 
Cases 
Maternal 
Mortality 
Percentage 
of Maternal 
mortality 
Viral Hepatitis 35 4 66.6 
Hepatitis B 11 1  
1. 
Hepatitis B+C 2 1  
2. HELLP Syndrome 4 2 33.3 
3. Chronic liver disease and 
PHT 
3 0 0 
4. Intrahepatic cholestasis of 
pregnancy 
2 0 0 
5. Malaria 2 0 0 
6. Leptospirosis 2 0 0 
7. Typhoid 1 0 0 
8. Combined malaria and 
leptospirosis 
1 0 0 
9. Gilbert’s disease 1 0 0 
 
19) RELATION OF MODE OF DELIVERY TO MATERNAL 
MORTALITY 
Mode of delivery did not alter the maternal outcome according to 
this study. 
TABLE – 19 
Sl.No. Mode of 
delivery 
No. of 
cases 
Percentage Maternal 
mortality 
% of 
maternal 
mortality 
1.  Labour natural 43 84.3 3 50 
2.  LSCS 5 9.8 2 33.3 
3.  Caesarian 1 1.9 1 16.6 
hysterectomy  
4.  Abortion 2 3.9 0 0 
 
20)  CAUSES OF MATERNAL MORTALITY 
The detailed analysis of various causes of maternal death is shown in 
Table 20. 
TABLE – 20. 
Sl. 
No. 
Causes of Maternal 
Mortality 
No. of cases Percentage of 
maternal 
Mortality 
1. Post partum haemorrhage 1 16.6 
2. Hepatorenal failure 1 16.6 
3. Hepatic coma 2 33.3 
4. Coagulation failure 2 33.3 
 
DISCUSSION 
The incidence of jaundice among the pregnant women attending the 
Govt. R.S.R.M. Lying-in Hospital, Royapuram, Chennai from January 
2004 to August 2007 is 1.26 per 1000 popultion. The incidence in various 
places by various authors is shown in the following table. 
Sl. 
No. 
Author Year Incidence per 
1000 
population. 
1. Bhaskar Rao (Madras) 1955 0.26 
2. Sarkar et al (Calcutta) 1992 2.3 
3. Reddi Rani et al 
(Pondicherry) 
1993 1.17 
4. Devinder Kaur et al (Delhi) 2001 0.92 
Our hospital incidence correlates with the study of Reddi Rani et al, 
1993.  Our hospital incidence is very high when compared to Western 
countries where it is 1 in 1500 pregnancies (Williams 1996). This is 
because of higher prevalence of malnutrition, poor sanitation and low 
socioeconomic status in our country. 
ETIOLOGY 
In the present study viral hepatitis was found to be the commonest 
cause (68.5%) next being HELLP syndrome (7.8%) third in order is chronic 
liver disease (5.8%).  Other causes are intrahepatic cholestasis of pregnancy 
(3.9%), malaria (3.9%), leptospirosis (3.9%), typhoid (1.9%) and Gilbert’s 
disease (1.9%). 
Patients with viral hepatitis was the major group with Jaundice in 
pregnancy consisting of 68%.  11 patients had acute hepatitis B infection 
(21.5%), [2 had combined hepatitis B & C infection (4%)] and 24 were 
presumptively taken as type E (47%).  Jaiswal  SP and Naik G in 2001 and 
Jain A, Sharma JK in 1999 analysed various types of viral hepatitis during 
pregnancy. Their studies were shown below : 
Place Author Year HAV HBV HCV HDV HEV No viral 
markers 
Indore Jaiswal SP  
Naik G 
Soni N 
2001 7% 19% 4% Nil 46% 24% 
New 
Delhi 
Jain A 
Sharma JK 
1999 4% 28% 2% Nil 42% 18% 
All HCV infected patients were coinfected with other hepatotropic 
viruses and the most common coinfecting agent was found to be HBV.  The 
prevalence of HAV, HCV and HDV were very low in the above studies. 
Because of universal exposure during infancy and childhood, HAV 
infection is more common in children rather than in adults in developing 
countries like India.  HDV always coinfects with Hepatitis B virus and 
cannot survive independently.  Hence acute viral hepatitis in an adult in a 
high prevalence country such as India is more likely to be HEV or HBV 
rather than HAV, HCV or HDV (Michael de Swiet, 2002). 
AGE :  
In the present study 58.8% of pregnant jaundiced women were 
between 20-24 years. This correlates with the study of Sheth Abhay et al, 
1990, Devinder Kaur et al, 2001 and Kamala Jeyaram et al, 1988. This 
age group is having the maximum fertility rate and maximum number of 
deliveries. Early age of marriage in lower socioeconomic group due to 
illiteracy also contributes.  (In Western Countries, only 30% are under 24 
years). 
GRAVIDITY 
In this study 59% of patients were primigravida;  It correlates with 
the study of Reddi Rani et al, 1993 and J.S. Chauhan et al, 1983 (50%).  
Kamala Jeyaram et al, 1986 and Devinder Kaur et al, 2001 had showed 
only  30%  incidence among primigravida. 
GESTATIONAL AGE 
76.4% of patients presented in 3rd trimester. This correlates well with 
the study of C.M. Alwani et al., 1986, Reddi Rani et al, 1993. Increaed 
incidence in third trimester is probably due to excess nutritional stress in 
late pregnancy. 
SOCIOECONOMIC STATUS 
95% patients belonged to lower socioeconomic group in this study. 
This shows the influence of malnutrition, poor sanitation, water 
contamination, sexual abuse and poor health awareness in the development 
of jaundice as stressed by various authors. 
SIGNS AND SYMPTOMS 
Analysis of symptoms shows majority of patients had fever (71%) 
followed by Anorexia, nausea and vomiting (55%). This correlates with the 
study of Subodh Singh R, Chauhan et al, 1991 and Jai Bagwan sharma 
et al, 1990.  In our study 96% of patients presented with jaundice. This is 
comparable with study of Kamala Jeyaram et al, 1988 (93%).  But 
Sunanda Kulkarni, 1996 has reported jaundice in only 60% of cases.  
Hepatomegaly was present in 16% of cases. 
BIOCHEMICAL PARAMETERS 
In this study, 57% of maternal mortality were with serum billirubin 
more than 10mg/dl.  In the study of Chadda et al, 1983 majority of 
mortality occurred with serum billirubin level more than 15mg.  50% of 
maternal mortality were observed with serum transaminase levels between 
100-400IU/L in our study.  Mortality also reported with low level and this 
is due to exhaustion by previous excessive release of transaminase (Issel 
Backer 1987). 
The prothrombin time is the most sensitive indicator of severity of 
liver dysfunction and hence the prognosis (Weinstein et al, 1982).  A 
mildly elevated prothombin time usually indicates concurrent DIC whereas 
grossly elevated prothombin time signify significant hepatic necrosis.   
Khuroo M.S. & Kamili in 2003 reported poor prognosis in patients with 
prothombin time > 30 secs.  In our study out of 6 maternal deaths 4 patients 
had prothombin time > 30 secs, one had 26 sec and other had 22 sec. 
COMPLICATION 
14 patients had anaemia. Among them 2 had severe anaemia (Hb < 
7gm%) and rest of them were between 7-10gm%. Among the 2, one patient  
died due to hepatic coma and other survived, but baby died within 24 hours 
of delivery. Among 4 pre-eclampsia patients 2 died. Anaemia and pre-
eclampsia in a jaundiced patient further worsens the prognosis. 
10 patients had PPH.  2 patients died of PPH (One had atonic PPH 
and other was due to DIC). Among 10 patients, 8 required blood 
transfusion. Alwani et al, 1985 reported 31% incidence of post portum 
haemorrhage in his studies.  Our study has significantly lower incidence of 
PPH (20%). 
MODE OF DELIVERY 
10% of patients were delivered by LSCS for obstetric indications 
and 85% had labour natural.  Since most were preterm, labour was easier. 
Mode of delivery did not influence maternal or fetal outcome. 
Early delivery by caesarian section to improve maternal and fetal 
survival and arresting the disease is recommended by  Peter’s et al, 1967 
and Burrough’s et al., 1983. However the risk of anaesthesia and bleeding 
due to coagulation abnormalities are the factors against it. 
FETAL OUTCOME 
Among the total 51 patients, 4% had abortion, 41% had preterm 
delivery and 55% had term deliveries.  Sheth Abhay et al, 1999 reported 
3% incidences of abortion and 55% preterm deliveries whereas Subodh 
Singh et al, 1991 reported 8%  abortion and 64% preterm delivery. 
Total number of fetal death is 13.  Among these 11 were preterm 
babies and only 2 was term. All neonatal deaths were because of 
prematurity and low brith weight.  Prematurity and low brith weight as a 
cause of neonatal mortality was stressed by various authors (Jai Bagwan 
Singh, 1990, Subodh Singh et al, 1991, Devinder Kaur et al, 2001). Fetal 
loss by abortion and prematurity may be due to high fever and general 
debility associated with high viraemia.  Perinatal mortality is 24%. 
MATERNAL OUTOME 
Out of 51 jaundiced pregnant women in this study, 6 women died.  2 
patients died of HELLP syndrome, 4 patients due to viral hepatitis. Among 
the 4 patients, one was positive for HBsAg and another was positive for 
both HBsAg and anti HCV. 
HELLP Syndrome 
HELLP Syndrome patients with jaundice constituted 4 patients, all 
of whom presented in late second and early 3rd trimester with severe 
hypertension. Weinstein et al, 1985 has reported the mean gestational age 
of presentation of HELLP syndrome was 33.6 wks. 
Among 4 patients, 3 were preterm delivery and one was intrauterine 
death.  Perinatal mortality in this group was 50% ( 2 out of 4).  Weinstein 
et al, 1985, Sibai et al, 1990 has reported a perinatal mortality rate of 60% 
in patients with HELLP syndrome. Higher perinatal mortality is due to 
prematurity.  There was 2 maternal deaths in this group.  One patient died 
due to acute renal failure. Though her pregnancy was terminated by preterm 
LSCS, patient didn’t recover. Another patient, whose pregnancy was 
terminated for IUD developed DIC. In spite of massive blood transfusion 
patient died.  Baha et al, 1990, reported a maternal mortality of 24% in his 
study, but it was high in our study (50%). 
Viral Hepatitis :  
Out of 35 patients due to viral hepatitis, there were 4 maternal 
deaths.  One patient had acute hepatitis B infection and she presented with 
term IUD.  Her pregnancy was terminated by LSCS due to failed induction 
but proceeded to caesarian hysterectomy due to atonic PPH.  Her 
prothrombin time was prolonged. Another patient had combined hepatitis B 
& C infection and she died of fulminant hepatic failure. The other 2 patients 
were negative for these 2 viral markers.  One patient died of hepatic coma 
and she had preterm delivery.   Another had LSCS done but died on I POD 
due to DIC.  Both babies were alive. 
Maternal mortality in this group was 12%.  Maternal mortality 
among pregnant women with viral hepatitis was 14.3% whereas is  
nonpregnant women it was 5.6% (De Swiet 2002). Age and parity did not 
reveal any significance. 
In the studies reported by Alwani et al, 1985 the cause of death 
among patients with viral hepatitis was hepatic coma in 2.4%, GI bleed in 
15%, Hepatorenal syndrome in 15%, PPH in 13% and Hepatic 
encephalopathy in 8%. Mirghani et al, 1992, observed more than 80% of 
deaths occurred in postpartum period.  It is concluded that pregnancy is a 
risk factor which increases the mortality of viral hepatitis. 
In the present study 63% had term delivery, 31.4% had preterm 
delivery and 5.7% had IUD.  Perinatal mortality calculated in this  group 
was 25.7%.  Observation in other studies includes, 
Author Year Abortion Preterm 
delivery 
Perinatal 
Mortality 
Medha et al 1993 8.3% 20% 27% 
Padmaker 1986 8.3% 24% 30.9% 
Alwani et al 1985 11.9% 18% 29% 
IHCP : 
There were 2 patients with intrahepatic cholestasis of pregnancy in 
the study. Both presented with pruritis and Jaundice for 2-3 wks duration. 
There was no clinical evidence of viral hepatitis in these patients.  One 
patient had term delivery and another one was borderline term.  Both babies 
were alive (Rioseco AJ, 1994) has reported an increased incidence of 
preterm labor (44% and 50% respectively) in IHCP patients.  But maternal 
and perinatal outcome was good in our study.  
Cirrhosis and Portal Hypertension :  
In 3 patients with chronic liver diseases, one had chronic active 
hepatitis due to combined Hepatitis B & C infection. She had oesophageal 
devascularisation done for variceal bleed 2 years before conception. She 
was on T.lamivudine 100mg bd throughout her pregnancy. She had 
uneventful term delivery and baby was alive. 
Another patient had cirrhosis and ascites and she landed in abortion. One 
patient with non cirrhotic PHT had preterm delivery but baby was alive. 
There was no maternal and perinatal mortality in this group except for one 
abortion. 
Maternal mortality is 4-7% in NCPHT whereas it is 10-18% in 
cirrhosis PHT (Shriram PV,  Goenka MK, 1999).  Perinatal mortality  in 
cirrhotic patient is 10 to 28% (Schreyer, P, 1982). 
Other Causes : 
One patient had combined malaria and leptospirosis. She presented 
at 22 weeks of pregnancy with H/o fever and vomiting for 1 week and 
Jaundice for 3 days.  Her serum Billirubin was 4 mg%.  She was intensively  
treated with T. chloroquine and inj. Crystalline penicillin. She recovered in 
2 weeks and was discharged.  At term she was readmitted in our hospital 
and had full term normal delivery without any complications. 
One patient with jaundice was widal positive and she presented at 26 
wks with H/o. fever, anorexia and  loose stools for 10 days.  Her serum 
billirubin was 3.8mg% and transaminase was elevated. She had preterm 
delivery but baby died due to low birth weight. Mother recovered. 
Two patients with jaundice and leptospira positive presented at II 
trimester.  Serum billirubin was more than 10mg% in both patients.  One 
patient  had abortion and other had stillbirth.  Both mother were  intensively 
treated and recovered.  Perinatal mortality is high in leptospirosis.  30% of 
pregnancies ended in abortion or preterm death (Shaked Y, Samra, D, 
1993). 
Two patients with fever, jaundice and spleenomegaly were positive 
for malarial parasites.  One patient had preterm labour and baby survived 
whereas the other patient had IUD during the treatment but mother 
recovered well. The incidence of preterm delivery, abortion, stillbirth and 
intrauterine deaths are frequent in malaria in pregnancy (15-60% by 
Brabin et al, 1990).  Maternal outcome is not so much affected except in 
cerebral malaria where maternal mortality is 40%. 
One patient who was diagnosed as Gilbert’s disease in previous 
pregnancy presented to us at 38 wks with H/o. jaundice and pruritis on a off 
for past 5 months.  Her billirubin level was 4mg%. She had uneventful 
delivery and baby was alive. 
MANAGEMENT 
In patients with HELLP syndrome immediate termination of 
pregnancy once diagnosed is the treatment of choice.  Strict control and 
frequent monitoring of BP is mandatory.  In IHCP, oral antihistaminic may 
provide some relief from pruritis, but UVCA is the preferred treatment.  If 
patient is anicteric, pregnancy can be  allowed to continue till term, 
otherwise pregnancy has to be terminated after completion of 36 weeks. 
Management of patients with viral hepatitis was entirely 
symptomatic and supportive.  It includes bed rest, high carbohydrate diet, 
glucose, vitamin B complex and IV dextrose.  In none cases, termination of 
pregnancy was carried out prophylactically.  Operative  interference was 
restricted to minimum. Tab. Chloroquine was given to patients with 
malarial hepatopathy.  Patients with leptospirosis was treated with 
crystalline penicillin.  Patients with typhoid fever was given Tab. 
Ciprofloxacin.  Patients with chronic liver disease did not require any 
specific therapy except for frequent monitoring of liver function tests and 
coagulation profile.  Blood and fresh frozen plasma were given when 
appropriate. 
FETAL ANOMALIES 
There was no congenital anomaly in the present study. Shah had 
reported that there is no convincing evidence that jaundice in the I trimester 
can cause fetal anomalies.  So jaundice is not an indication for medical 
termination of pregnancies. 
DEVELOPMENT OF NEONTAL JAUNDICE 
4 babies had only physiological jaundice. A jaundiced  mother 
giving birth to a jaundiced baby is rare because in most cases, conjucated 
billirubin is present to which placenta is impermeable (Sechar). 
TRANSPLACENTAL TRANSMISSION OF HBsAG 
The cord blood of 11 babies of HBsAg positive mothers were tested 
for HBsAg. All but one were negative for HBsAg. All babies received 
immunoglobulin and vaccination. 
SUMMARY 
1) Incidence of jaundice in R.S.R.M. Lying-in Hosptial, Chennai during 
the year 2004 to 2006 was 1.26 per 1000 pregnant women. Total 
number of cases were 51. 
2) Viral hepatitis is the commonest cause (35 cases constituting 68%) 
3) Out of these 35 cases  of viral hepatitis, 11 had hepatitis B infection (2 
had combined hepatitis B  & C infection). 
4) 58.8% were in 20-24 year age group.  Fulminant  hepatic failure is also 
higher in this age group. 
5) Primigravidas constituted 58%. 
6) The maximum incidence was in III trimester (76.4%). 
7) The mortality was more in puerperium. 
8) These people belonged to lower socioeconomic group. 
9) Maternal and fetal prognosis were worse with  high levels of serum 
billirubin, but prognosis was affected by low levels also. 
10) Very high levels of serum transaminase indicate marked hepatocelluular 
damage and bad prognosis. Sudden fall to low levels is also ominous. 
11) Serum alkaline  phosphatase levels were raised to high levels in 
intrahepatic and extrahepatic cholestasis.  It did not correlate with the 
prognosis. 
12) Serum prothombin time is a good indicator of prognosis.  PT of > 30 
secs indicates worse prognosis. 
13) Anaemia and PIH in a pregnant jaundiced women worsens the 
prognosis. 
14) Maternal and perinatal outcome was good in intrahepatic cholestasis of 
pregnancy. 
15) In HELLP syndrome with jaundice maternal and perinatal mortality was 
50% respectively. 
16) Perinatal mortality is high in jaundice due to malaria, leptospirosis and 
typhoid. 
17) No significance could be given to the mode of delivery in relation to 
maternal and fetal outcome. 
18) Incidence of preterm delivery is 41.1% 
19) 60% of babies were weighting < 2.5kg. 
20) Perinatal mortality in pregnancies complicated by Jaundice is 25.4% 
(254/1000 livebirth). 
21) Low birth weight and prematurity predisposed to high fetal loss. 
22) Maternal mortality among jaundiced patients is 11.76%. 
23) Viral hepatitis contributes maximum to the maternal mortality (66.6%). 
Two deaths were due to Hepatitis B infection. 
CONCLUSION 
Jaundice in pregnancy may be caused by several factors.  But in 
developing countries like India, the commonest cause is viral hepatitis  (as 
proved in the study), mostly due to  waterborne non B type (HEV).  Next in 
frequency is followed by HBV and then HCV. Acute viral hepatitis in an 
adult in a high prevalence country such as India is most likely to be due to 
HEV or HBV rather than HAV or other viruses.  
The maternal mortality in pregnant women with viral hepatitis is 
14.3% and in non-pregnant women it is 5.6% indicating a high relative risk 
of death (4:1) for pregnancy.   The high maternal and fetal wastage 
attributable to viral hepatitis clearly shows that the problem of viral 
hepatitis in pregnancy needs to be addressed. 
Anaemia, pre-eclampsia and post partum haemorrhage in a 
jaundiced pregnant women carries worst prognosis. Because of high 
endemicity, malaria and leptospirosis also contributed significantly to the 
cause for jaundice in our study.  Perinatal mortality were high in this group. 
Perinatal mortality in jaundice complicating pregnancy is mainly due 
to prematurity and low birth weight.  Other major area of concern is the risk 
of vertical transmission of HBV. This can be greatly minimized by giving 
HBV immunoglobulin and vaccine to the newborn immediately after 
delivery.  Vertical transmission of HCV is rare unless there is HIV 
coinfection or high degree of viraemia. 
To conclude all pregnant women should be screened for HBsAG as a 
routine.  Health education, good hygiene, provision of safe water and 
improvement of basic sanitation will help to prevent disease transmission.  
To reduce the incidence of hepatitis B at the root level, Hepatitis B 
vaccination should be given to all newborn. 
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PROFORMA 
S.No.: 
Name:     Age: 
Unit:   I.P.No.  DOA:   DOD: 
Address: 
LMP:    EDD: 
G: P: L: A: 
 
COMPLIANTS      Duration 
H/O Pain : 
H/O Bleeding PV : 
H/O Draining PV : 
H/O Nausea, Vomiting : 
Anorexia : 
Purities : 
Malaise  
H/O Fever  
GI Bleed  
Jaundice  
Oliguria  
Haemetemesis  
Edema legs  
Altered Sensorium/Loss of Consciousness  
Indigenous Treatement : Tab./Inj.  
GENERAL EXAMINATION 
Built     Pulse:    BP: 
Anemia    CVS:    RS: 
Icterus   CNS: Higher Funtion 
Fever      Hltered Sensorium 
PE      Flap 
Spider Naevi   Abdomen 
Palmar erythema    Ascitis 
Flap      Distended Veins 
      Hepatomegalay 
      Splenomegaly 
OBS. EXAMNIATION 
PA: Uterus:   PV: 
Presenting Part: 
FH: 
INVESTIGATION 
Urine: Albumin/Sugar/Deposits  C/S: 
BS/BP:       Urobilinogen: 
Blood Grouping:      Complete 
Hemogram: 
 BT: CT: Peripheral Smear:  Platelet Count: 
Blood Urea:  Blood Sugar:  Sr. creatinine: 
Sr. Uric Acid: 
LFT: SGOT/SGPT/SAP 
Total Proteins/Albumin/ Globulin: 
Sr. Viral Markers  : 
Sr. Fibrinogen  : 
VDRL  : 
Sr. Electrolytes  : 
Blood for leptospirosis : 
OBS.OUTCOME 
 Abortion/IUD/Still Birth/Preterm/Term: 
Nature of delivery 
 Labour Natural/Labour Natural with episiotomy 
 Forceps/Vacuum/LSCS 
 Third Stage of Labour 
 PPH: 
BABY DETAILS: 
 Baby Sex/Wt/Apgar/Jaundice/Cord Blood. 
TREATMENTS GIVEN 
 IV Fluids/Antibiotics/Diuretics/Inj.Vitamin K/Others 
 Blood Transfusion/FFP 
CLINICAL DIAGNOSIS 
MATERNAL OUTCOME 
FETAL OUTCOME 
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1 Vinotha 27 G2P1L1 34 1,2 1Week 1 1,2,3 ++ - 8min 14min 26sec 7.4 85000 4.6 260 217 - - - - - PT LSCS 2.1 D - HRF
2 Latha 20 Primi 40 2,3,5 3days 1 - - + N N N 11 2.4 5 110 200 - - - - - Term LN 2.5 A - -
3 Sasikala 24 G2P1L1 36 1,2,3,6 17days 1,3 - + + N N N 9 2.1 6 80 140 - - MP+ - - PT LN 1.9 A - -
4 Indumathi 20 G3P1L1A1 29 3,5 10days 1,2,3 1 - + N N N 8 1.75 8 140 186 - - MP+ - - IUD LN 1.7 A - -
5 Sathiya 22 Primi 37 1,2,3,7 4days - 1 - + N N N 8.5 2 4 110 140 + - - - - Term LN 2.8 A + -
6 Kala 23 Primi 36 5,6,9 25days 1 - - + N N N 10 2.1 6 135 652 - - - - - B. Term LN 2.2 A - -
7 Govindammal 25 G3P2L2 26 1,2,3,7 10days 1 - - + N N N 9 2.4 2.8 80 317 - - - + - PT-ND LN 1.3 A - -
8 Lathifa 26 Primi 37 3,4 1Week 1 - - + N N N 12 2.2 6 128 113 + - - - - Term LN 3 A - -
9 Revathi 29 Primi 36 3,8 12days 1 - - + N N N 11 2.1 2.5 60 90 - - - - - Term LN 2.5 A - -
10 Kavitha 22 G2P1L1 26 5,8 8days 1,2,4 - - + N 11min 21sec 10 2.1 4.5 120 170 - - - - - PT-ND LN 1.4 A - -
11 Santhi 32 G3P2L2 40 2,3 3days 1 1 - + N N N 6.8 2.1 7 160 146 + - - - - Term-ND LN 2.8 A + -
12 Manjula 24 Primi 34 1,3,5 7days 1,2 1 - + N 10min 19sec 8 2.4 6 80 96 + - - - - PT-ND LN 1.8 A + -
13 Veeralakshmi 19 Primi 34 4 1Week 1,2,5 1 - + N 13min 46sec 6 2.1 2.8 518 255 - - - - - PT LN 1.8 D - Hepatic coma
14 Leema 25 G2P1L1 27 1,2,3,4,66days 1 - + + N N N 9.2 2 16 250 117 - - - - + Stillborn LN 1.3 A - -
15 Desammal 20 G2P1L1 20 1,3 5days 1 - - + N N N 9.2 1.8 4 60 113 - - MP+ - + Term LN 2.7 A - -
16 Tamilselvi 21 Primi 38 1,2 1 Month 1 4 - + N N 17Sec 10 2.2 4 52 125 + + - - - Term LN 2.7 A - -
17 Prema 32 G3P2L2 22 2,4,6 20days 1,3,4 1,5 - - N N N 7 1.7 6 92 140 - - - - - Abortion - - A - -
18 Ammu 29 Primi 38 5,6,9 1 Month 1 - - + N N N 11 2.1 4.5 110 550 - - - - - Term LN 3 A - -
19 Usha 29 Primi 36 2 1days 1 2 +++ + 2min 7min N 11 95000 2.8 96 112 - - - - - PT LN 2 A + -
20 Jayanthi 24 Primi 40 2,4 2days 1 - - - 6min 20min 32sec 10 1.3 6.2 132 217 - - - - - Term LSCS 2.8 D - DIC
21 Rathidevi 23 Primi 39 1,3,5 4days 1 - - + N N N 11 2.3 9 120 196 + - - - - Term LN 2.3 A - -
22 Vasantha 22 G2P1L1 28 1,2 3days 1 2 ++ + N N N 9 100000 3 484 207 - - - - - PT-ND LN 1.5 A - -
23 Rani 23 Primi 34 1,2 3 Months 2,3 5 - + N N 20sec 9.8 2.1 2.6 60 80 - - - - - PT LN 1.8 A + -
24 Kalaiselvi 23 Primi 32 1,2,4 2days 1 2 +++ + 6min >20min 22sec 8.6 65000 18 80 310 - - - - - IUD LN 1.8 D + DIC
25 Kaniammal 20 Primi 20 2,3 1Week 1,2 1 - + N N N 7.8 1.9 10 160 380 - - - - + Abortion - - A - -
MASTER CHART
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26 Chitra 23 Primi 38 6 5 Months 1 6 - + N N N 11 2.6 4 30 75 - - - - - Term LN 2.6 A - -
27 Naleeni 22 Primi 33 2,3,6 6days 1 - + + N N N 12 1.75 12 240 180 + - - - - IUD LN 1.6 A + -
28 Vasanthi 34 Primi 38 3,4,5 2days 1 - - + N N N 12 2.2 5 126 117 + - - - - Term LSCS 2.9 A - -
29 Pushpa 22 Primi 34 1,3,4,5 7days 1 - - + N N N 10 2 4 200 115 - - - - - PT LN 2.4 A - -
30 Veerama 27 Primi 34 1,3 10days 1 - - + N N N 10 2.1 4.8 80 90 - - - - - PT LN 2.5 A - -
31 Amsha 27 G2P1L1 38 1,4,6 6days 1 1 - - N N N 8 2.1 2.5 170 96 - - - - - Term LN 3 A - -
32 Selvi 29 G3P2L2 40 1,3,5 9days 1 1 - + N 13min 51sec 7 1.85 12.6 430 300 + - - - - IUD LSCS+H* 3.1 D + Atonic PPH
33 Megala 20 Primi 26 3,5 10days 1 1 - + N N N 7 2 4 118 260 - - - - - PT-ND LN 1.25 A + -
34 Sumathi 26 G2P1L1 35 2,3,5 2days 1 - - + N N N 10 1.95 12 178 210 - - - - - PT-ND LN 1.9 A - -
35 Uma 27 G2P1L1 39 1,2,3 10days 1 1 - + N N N 7.8 2.1 5 110 178 + - - - - Term LN 2.2 A - -
36 Dilliammal 23 Primi 38 1,3,4,5 3days 1,2 1 - + N 15min 59sec 8 1.8 14 226 215 + + - - - Term LN 3 D - Acute Liver Failure
37 Padma 35 G3P2L2 40 1,3,4,5 9days 1 - - + N N N 10 2.1 4.6 80 90 - - - - - Term LN 3.2 A - -
38 Bhavani 22 Primi 38 1,3 5days 1 - - + N N N 13 2.5 5 98 110 - - - - - Term LN 2.25 A - -
39 Gowri 23 G2P1L1 40 1,3,5 3days 1 - - + N N N 10 2 4 80 178 - - - - - Term LN 2.25 A - -
40 Jayanthi 22 Primi 36 1,3 4days 1 - - + N N N 13 2.2 5 110 136 - - - - - Term LN 2.6 A - -
41 Kaniammal 26 G4P3L3 39 1,6 2days 1 - - + N N N 9 2.2 5 86 103 - - - - - Term LN 2.4 A - -
42 Kanagi 30 G3P2L2 35 1,3,4 7days 1 - - + N N N 9.6 2.1 6.1 250 215 - - - - - PT LN 1.9 A - -
43 Hema 26 G2P1L1 33 1,3 2days 1 - + + N N N 10 2.3 6 86 95 - - - - - PT LN 1.7 A - -
44 Kamala 25 Primi 34 1,3,5 6days 1 - - + N N 18sec 10 2 4 200 210 - - - - - PT LN 2 A - -
45 Vadivu 22 G2P1L1 40 1,6 6days 1 - - + N N N 9 2.1 3 78 212 - - - - - Term LN 2.9 A + -
46 Nirmala 22 Primi 39 3,4,5 3days 1 - - + N N N 12 2.4 6 110 176 - - - - - Term LN 2.6 A - -
47 Santhi 23 Primi 38 1,3,5 8days 1,2 - - + N N N 12 2.2 3.9 140 193 - - - - - Term LN 2.75 A - -
48 Jamuna 20 Primi 39 1,3,6 4days 1 - - + N N N 10 2.3 4 100 98 - - - - - Term LSCS 3.6 A - -
49 Mary 19 Primi 38 1,2,3 4days 1 - - + N N N 12 2.6 5.5 105 90 - - - - - Term LSCS 3.7 A - -
50 Balkish 21 Primi 41 1,2,3 6days 1 - - + N N N 11 2.6 5 118 112 - - - - - Term LN 2.5 A - -
51 Meena 24 G2P1L1 27 1,3,6 10days 1 1 - + N N N 7.4 2.1 5 130 72 - - - - - PT-ND LN 1.1 A - -
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Type of Disease
RELATION OF TYPE OF DISEASE TO MATERNAL 
MORTALITY
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MATERNAL MORTALITY IN RELATION TO GRAVIDITY
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Mode of delivery
RELATION OF MODE OF DELIVERY TO MATERNAL 
MORTALITY
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CAUSES OF MATERNAL MORTALITY
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ANALYSIS OF PRESENTING SYMPTOMS
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